We present an overview of some concepts and methodologies we believe useful in modeling HIV pathogenesis. After a brief discussion of motivation for and previous efforts in the development of mathematical models for progression of HIV infection and treatment, we discuss mathematical and statistical ideas relevant to Structured Treatment Interruptions (STI). Among these are model development and validation procedures including parameter estimation, data reduction and representation, and optimal control relative to STI. Results from initial attempts in each of these areas by an interdisciplinary team of applied mathematicians, statisticians and clinicians are presented.
Introduction -HIV Modeling and STI
Although the correlates of immune protection in HIV infection remain largely unknown, our knowledge of viral replication dynamics and virus-specific immune responses has grown. Concurrent with these advances, there has been an abundance of mathematical models that attempt to describe these phenomena. The models proposed have principally been linear and nonlinear ordinary differential equation models, both with and without delay terms. While data fitting problems motivated the development of some models, others have been proposed in a more abstract sense to suggest new experiments or possibilities for ways in which the body interacts with this pathogen. Mathematical models alone cannot answer questions about the pathogenesis of HIV infection or similar biological processes. But when used in conjunction with data as part of designed experiments, models can be a powerful tool in understanding mechanisms in complex systems. Moreover, data-oriented mathematical models can also stimulate further clinical and laboratory research. In any discussions of mathematical modeling of complex systems, it is appropriate to point out that while complex models may be needed to provide accurate descriptions of the underlying dynamics, the models are most useful when they can be compared to clinical and/or experimental data. In developing models for HIV infection and treatment, this requires that a balance be struck between complexity and utility.
We begin this paper with a brief summary of issues that have arisen in the development of models for HIV infection and motivate the model fitting problem. We also offer an introduction to STIs as a potentially improved treatment strategy and indicate how mathematical control theory can be helpful in finding treatment schemes. This background will set the stage for the model-and data-based examples that follow.
Models for HIV Infection
Numerous factors have been considered in modeling HIV infection as one must typically choose only a critical subset of the many possible biological compartments and interactions. Moreover, scale is important in that one must decide whether to model at the micro level of viral RNA or more at the systemic level. Our focus is on compartmental models in which compartments each typically correspond to a type of cell population throughout the body. We do not attempt to provide a comprehensive survey of the extensive collection of mathematical models used with HIV infection. Rather, we refer the reader to one of the excellent survey articles already published; see, for example, [14] and [53] . We provide a brief overview of some important developments here.
Investigations of the kinetics of virus and CD4+ T-cell populations using mathematical models with data from patients undergoing Highly Active Anti-Retroviral Therapy (HAART) support the theory of very rapid and constant turnover of the viral and infected cell populations in all individuals studied; see, for example, Ho, et al., [29] , Wei, et al., [65] and Perelson, et al., [55] . This contrasts with researchers' previous assumptions that the stable viral and CD4+ T-cell concentrations seen during the period of clinical latency of chronic HIV infection were due to the absence of any significant viral replication. The studies by Ho, Wei and Perelson indicate that both the viral and infected cell populations are turning over rapidly and continuously. Further work by Perelson, et al., [54] revealed a second population of longer lived infected cells contributing to the population of viral RNA. Since these reports, numerous groups have used mathematical models to estimate decay rates for infected cell populations [41, 43, 45, 46, 68] . In Section 2 we present a model that can predict the observed persistent low-level replication of virus and includes multiple infected cell populations.
The early linear models developed in [65, 29, 55, 54] are approximations to more realistic nonlinear models for viral and infected cell decay, and thus are applicable only over short periods of time, most likely on the order of days. While these linear models have been extremely useful in characterizing short-term dynamics of HIV infection after therapy, several researchers have attempted to use these models to estimate time to eradication of virus from individuals. Such predictions involve periods of time which extend beyond that which is appropriate for approximation of the nonlinear dynamics by a linear model.
To model data over longer periods of time and make predictions about long term outcomes, nonlinear mathematical models are necessary. In addition to the unrealistic simplifying assumptions that make it difficult for linear models to accurately describe long-term HIV infection dynamics, factors that could play an important role in dynamic disease outcomes may be omitted in linear models. For example, several authors have raised the question as to whether or not these linear mathematical models have adequately described the decay of compartments relevant to HIV infection dynamics. The authors of [8] argue that more complex nonlinear models are needed to accurately describe long-term viral decay. In [41] the authors point out that the biphasic pattern which has been attributed to two populations of infected cells could be the result of exponential decay of a single population of infected cells with decreasing exponent over time. This phenomenon is well-known in population biology, and is often referred to as density-dependent decay.
Viral production by cells infected with HIV depends on the "age" (e.g., time since infection) of the infected cells and there are several different biological aspects of this age dependence. Intracellular delay due to viral reverse transcription, integration, transcription, and virion formation is described by Mittler [44] , extending the work of Perelson, et al., [54] . Mittler allows intracellular delay to vary across cells, and estimates these delays to be more significant than the pharmacological delays associated with drug absorption. Recent efforts [5] with in vitro data suggest the importance of modeling these distributed delays with some care. Incorporation of this variability of delays into models may lead to improved estimates of the half-life of free virus from short-term clinical data on patients undergoing HAART.
Since the qualitative behavior of a dynamical system is determined by its underlying parameters, knowledge of the bifurcation properties of the system is important for understanding the associated characteristics of the biological system described by the model. If the range of model parameters for a population is such that dramatically different outcomes are predicted for different individuals, bifurcation values for different parameters could suggest target interventions for continued successful treatment. For example, loss of stability of the zero steady state for viral load could be reversed by treatments affecting the parameters which influence this stability. In addition, variability in initial conditions, which one can consider as parameters in the model, can lead to trajectories of the system lying in different regions of attraction, i.e., different initial population sizes can lead to dramatically different qualitative outcomes in a nonlinear model. Such situations are described in [9, 67] for Structured Treatment Interruption (STI) studies, discussed below. The models in these reports and that discussed in Section 2 have multiple equilibria; different equilibria describe the success or failure of the immune system to control infection and the initial conditions and parameters of the system determine which equilibrium is realized. Careful qualitative analysis of mathematical models that describe HIV infection dynamics can contribute to understanding of fundamental qualitative features of infection, and possibly suggest targets for improved disease monitoring and/or treatment.
In using any of these complex models, one would like to understand the identifiability of parameters, i.e., which parameters can be successfully estimated and with what type of data. In Section 3, we examine the ability to estimate parameters in a typical nonlinear model of HIV infection dynamics. In doing so, we describe a relevant inverse problem methodology, including sensitivity analysis, the generalized least squares method, and estimation of standard errors in the estimation process.
The complexity of nonlinear HIV models and data sets may necessitate the extraction of only essential states or information in order to successfully fit models to data. In Section 4 we demonstrate the use of the proper orthogonal decomposition (POD) method to capture essential elements of actual HIV patient time series data. This data reduction technique is similar to the singular value decomposition or principal component analysis often seen in statistical literature and could be used to reduce the dimensionality of ODE model solutions as well. While this tool may not be helpful for determining variability of individuals in a population, it can help determine the essential characteristics which pervade the entire population. One possibility is to fit ODE models to the obtained essential basis elements, rather than to the noisy aggregate population data.
STIs and Control Theory
In spite of the early hopes of a cure for HIV infection with potent antiretroviral therapy, it has become apparent that suppression, and not eradication, is most likely the best that can be achieved with this strategy. The current strategy of continuous combination therapy is difficult to maintain for long periods of time due to short-and long-term toxicities (metabolic abnormalities, body habitus changes, lipid abnormalities, mitochondrial toxicity and liver toxicity) as well as adherence challenges inherent in these complicated pill regimes, cost, and the development of resistance to medications.
Consequently, strategies have been sought that can decrease the side effects for and medication burden placed on patients while maintaining some control over HIV replication through an individual's immune system. Excitement for such strategies surfaced with the reporting of the "Berlin patient" [36] , a patient initially treated during the course of seroconversion, who interrupted therapy temporarily twice within the first 6 months of treatment and then permanently stopped treatment and maintained control of HIV replication.
Numerous authors have discussed the effect on immune response as antigen declines [18, 12, 17, 48, 49, 15, 25, 32, 61, 51, 56, 10, 59] , which suggests that viral replication is required to maintain an HIV-1 specific Cytotoxic T Lymphocyte (CTL) response. These observations are supported by data in [32, 61] where it is observed that HIV-specific CTL activity increases in patients who experience viral rebound, either as a spike during ongoing suppression or as the result of changes in treatment regimen. These results, combined with the data on the "Berlin patient," have led a number of investigators to propose methods of immune stimulation through vaccine or structured treatment interruption (STI) once patients have successfully suppressed viral replication. Hence, an underlying premise in treatment interruption is that allowing virus to replicate stimulates the immune system and may even cause some patients to "self-vaccinate."
In an ideal scenario, individual immune response would be stimulated and augmented sufficiently through a number of interruptions to the point where patients control their infections without need for the cumbersome treatment regimens currently available. Initial investigations aimed at assessing immune response to viral replication through treatment interruptions offer promise. Control of viremia during therapy discontinuation has been associated with successful HIV-1 specific immune response [36, 17, 50] . A good overview of the concept of STI and its promise in several scenarios is offered by Lisziewicz and Lori [37] .
Many studies of treatment interruption assess changes in HIV-specific immune response [58, 27, 52, 23] . In investigations of treatment interruption in acutely infected individuals [50, 57] , HIV-specific immune responses were associated with control of viremia. Ortiz, et al., [50] note the role of broad and strong CTL response in tandem with neutralizing antibodies in association with control of viremia after drug discontinuation. Rosenberg, et al., [57] , report increased and sustained HIV-specific CTL response during one, two, or three treatment interruptions, and, once CTL response was established, eventual control of viremia in all 8 patients studied. These examples support the inclusion of immune response as a factor in any model of HIV infection to be used in STI studies. They also suggest that a realistic model should take into account the possibility of little or no immune response in some situations and a strong HIV-specific immune response in others. The model discussed in Section 2 below tries to capture these features.
The cited studies have involved small numbers of patients and most do not employ standardized protocols for interruption schedules (e.g., see [58] ). Two of the primary questions associated with STI are: (i) Is there an optimal duration of therapy needed in order to benefit from structured treatment interruption? (Shorter lengths of initial therapy may limit the number of toxicities and inconveniences experienced by patients but may not be sufficient to maximally suppress HIV in all body compartments to allow for controlled viral replication in a structured interruption setting); (ii) Can the host immune system be augmented through repeated exposure to viral antigens so as to control HIV infection without the use of anti-retroviral therapies? There is data to suggest that repeated exposure to antigen stimulates the immune system. Moreover, some individuals appear to control their infections after treatment interruptions with little or no need for further treatment.
In principle, these questions may be addressed using standard comparative statistical analysis techniques if sufficient numbers of subjects are randomized to different regimens (e.g., length of therapy). However, questions about the relationship between antigen level and immune response or factors which influence biological mechanisms associated with host immune control of infection may be more appropriately addressed through the use of mathematical modeling (including such models as those referenced above in Section 1.1) with formal estimation of and inference on biologically meaningful parameters combined with control theory.
Previous efforts on mathematical modelling of treatment interruption have been reported in [67] and [9] . Wodarz and Nowak [67] employ a mathematical model which represents uninfected CD4+ T-cells, infected CD4+ T-cells, CTL precursors (immune memory), and CTL effectors. Bonhoeffer, et al., [9] use a model incorporating uninfected, actively infected, and latently infected T-cells, as well as immune response (CTL effectors). Both investigations offer important theoretical insights into immune control of virus based on treatment strategies. In what follows, we utilize another model that incorporates some of the ideas from these papers in the context of STI scenarios.
A number of researchers [11, 13, 20, 31, 35, 66] have begun to consider theoretical control of HIV infection models in attempts to suggest optimal treatment strategies. Open loop control for differential equation models is considered in [13, 35, 20] to develop strategies for treatment in primary infection. Other authors [11, 66] use feedback controls, i.e., control laws chosen in a real-time fashion based on current observations of the (full) state of the underlying dynamical systems. In these studies the "controls" range from chemotherapy to combination strategies, e.g., see [31] , in which treatments enhancing the immune system component of the model are combined with those that directly delay progression of disease.
For example, to control the dynamics of the mathematical system that describes the viral and immune system dynamics during structured treatment interruption, one might consider a scaled periodic control input u(t) (therapy) that is zero for some time ∆t 1 and then rises with constant slope (linearly) to a value of one, remains there for time ∆t 2 , and then ramps linearly back to zero. This input affects states and parameters in the dynamic model that are related to infectivity. A cost functional, established in collaboration with clinicians, subject to the infection dynamics, could then be investigated. In a typical situation one might minimize the cost functional over permutations of treatment schedules; the free parameters would then be ∆t 1 and ∆t 2 in the control u(t), yielding a treatment that is in some sense, optimal. We demonstrate open loop control theoretic techniques for solving this problem with examples of continuously variable drug control (Section 5) and discrete (STI-like) control (Section 6).
Eventually, one should investigate these types of control problems in the context of patient data. Since patient data for immune response and antigen behavior are collected relatively infrequently and involve only partial state observations, a compensator theory combined with state feedback for nonlinear systems must be developed. Mathematical tools for closed-loop or feedback control of Structured Treatment Interruption for specific models are still needed. One must also determine the type and quantity of data on a patient's current health that would be required to successfully carry out an optimal or sub-optimal feedback control-based STI.
In the remainder of this paper, we discuss mathematical issues and tools relevant to STIs for HIV infection. Rather than purporting to provide a specific solution for HIV treatment, the nature of our presentation is more to demonstrate these tools with examples that may be pertinent to data available from clinicians. We suggest mathematical methods for solving some of the related problems and point out where further developments are needed.
A Model for Control and Parameter Estimation
In this section we discuss a number of important issues encountered in attempting to formulate a dynamic model of HIV progression in an individual. Desirable features in a model to be used with clinical observations of treated and untreated patients are presented. In addition to summarizing some of the difficulties in choosing a model, we ultimately must formulate a "typical" model to be employed in the subsequent discussions of mathematical and statistical methodologies presented in the remaining sections of this paper. Given this goal and given the existence of several recent survey papers on models noted in the Introduction, we do not include here discussions of all the important aspects of modeling of HIV. Nor do we represent that we have a good model of HIV progression and treatment; rather we have a model that contains some of the more desirable features one could expect! A wide variety of mathematical models have been proposed to describe various aspects of in-host HIV infection dynamics. The most basic of these models typically include two or three of the key dynamic compartments: virus, uninfected target cells, and infected cells. A model used for estimation and control should include these compartments at a minimum. Infected and uninfected CD4+ T-cells are not usually censused separately, so they may need to aggregated for purposes of model fitting, i.e., the estimation of mechanisms and parameters in a model. However, current knowledge of the infection process justifies incorporation of three distinct physiologically relevant compartments. In addition, the documented importance of the immune system in responding to HIV infection (and especially its aparent crucial role during structured treatment interruptions) strongly motivates the inclusion of at least one model compartment representing immune response to the pathogen. We thus seek a model that includes some measure of cytotoxic T-lymphocyte (CD8) response to HIV infection. The incorporation of these compartments is important when relating the model to observable quantities in patient data.
A model used to suggest treatment strategies should be capable of incorporating the action of commonly used reverse transcriptase (RT) inhibitors and protease inhibitors (PIs). Inclusion of the latter usually implies inclusion of a compartment for virus rendered non-infectious by the PI. Given the predominance of HAART in the form of drug cocktails combining two or more drugs, the model should behave reasonably when simulating multi-drug therapy. In spite of these comments, the model we will employ herein only includes RT inhibitors, but this aspect could be readily generalized.
As pointed out by Callaway and Perelson [14] in their 2002 review paper, a reasonable model of HIV infection predicts a non-zero steady-state viral load in the presence of drug therapy. Patients who are subject to drug therapy often successfully suppress virus for a long time, potentially at undetectable levels. However, some reservoir exists which almost always causes the virus to grow out again upon removal of drug therapy. Hence we do not expect incorporation of drug therapy in the model, at a sensible efficacy, to drive the viral load to zero, but rather reduce it considerably, perhaps below the assay limits of detection. The authors of [14] note that many models typically employed to describe HIV infection do not exhibit a reasonable relationship between drug efficacy and the viral load. In these models, a very slight change in drug efficacy can yield a drastic change in the viral load equilibrium. This has important consequences for the control problem -a successful model must exhibit reasonable sensitivity of the viral load equilibrium to treatment efficacy.
The model we provide as an example is adapted from one proposed by Callaway and Perelson (denoted (5.3) in [14] ). Our modified system of ODEs is given by Type 1 target:
Free virions:
This model entails two co-circulating populations of target cells, perhaps representing CD4 T-lymphocytes (T 1 ) and macrophages (T 2 ). The drug efficacy parameter models a reverse transcriptase (RT) inhibitor that blocks new infections and is potentially more effective in population 1 (
, where the efficacy is f , with f ∈ [0, 1]. As in the Callaway-Perelson paper, we only model an RT inhibitor, though again, it is simple to incorporate a PI. The populations of uninfected target cells T 1 and T 2 may have different source rates λ i and natural death rates d i .
As is common in models of HIV infection, infected cells T * i result from encounters between uninfected target cells T i and free virus V . The natural infection rate k i may differ between the two populations, which could account for believed differences in activation rates between lymphocytes and macrophages. The differences in infection rates and treatment efficacy help create a low, but non-zero, infected cell steady state for T * 2 , which is commensurate with the idea that macrophages may be an important source of virus after T-cell depletion. Infected cells may be removed from the system via either natural death or by the action of immune effector cells E described below. For our efforts here we assume that both target cell types have the same death rate δ, though this could be readily generalized as well.
To preserve simplicity in the model, we omit the chronically infected cell compartments proposed in the original Callaway-Perelson model. The important qualitative behaviors seem preserved in the model we propose and specifically modeling this feature is not essential to our present work. In particular, the existence of a low steady-state viral load equilibrium and sensitivity of the viral load equilibrium to the drug efficacy is obtained with or without such compartments. We note that while removing the chronically infected compartments does not affect the sensitivity to treatment, the addition of immune response terms does, as discussed below.
Free virus particles are produced by both types of infected cells, which we assume produce virus at the same rate (again this could be easily generalized to account for different productivity). In the Callaway-Perelson model, virus only leaves the V compartment via natural death at rate c; there is no removal term in theV equation representing loss of virus due to infection of a cell. One potential justification for this omission is offered by Nelson and Perelson [53] (page 10) who suggest that this term can be ommitted since the term k i T i V is small in comparison to cV in the typical HIV-infected patient. They further assert that if T i is approximately constant, one can absorb the loss of virus due to infection into the cV term, thus making it account for all clearance processes.
While the arguments offered by Nelson and Perelson could justify the exclusion of the virus removal term, we investigate situations where treatment is interrupted abruptly, potentially effecting drastic changes in all of the cell populations under consideration. We therefore include the term
V in theV equation to account for the removal of free virus that takes place when free virions infect a T 1 or T 2 cell. We make the simplifying assumption ρ i = 1, i.e., one free virus particle is responsible for each new infection. This could easily be adapted for multiple virus particles being responsible for each new infection by choosing
Finally, the immune effectors E, or cytotoxic T-lymphocytes, are produced in response to the presence of infected cells and existing immune effectors. The immune response assumed here is similar to that suggested by Bonhoeffer, et al., in their 2000 paper [9] , with a Michaelis-Menten type saturation nonlinearity. The infected cell dependent death term in the immune response represents immune system impairment "at high virus load". In [9] , the authors demonstrate that a model with this structure of immune response and a latently infected cell compartment can exhibit transfer between "healthy" and "unhealthy" stable steady states via STI, making it a good candidate for our investigation. We also add a source term λ E to create a non-zero off-treatment steady state for E. While immune effectors are not inherently present, some small persistence of them is to be expected during infection. We note that other immune responses models, such as those considered by Wodarz-Nowak [67] or Nowak-Bangham [47] could be substituted, if desired. However, the latter does not appear to admit multiple stable off-treatment steady states.
The immune response we model is that of cytotoxic T-lymphocytes (CTL). CTL act by lysing infected cells, causing them to explode. Thus CTL remove infected cells from the system in the equations forṪ * 1 andṪ * 2 , at rates m 1 and m 2 , respectively. Unlike interferons, they do not directly target free virus, so there is no interaction term with the virus compartment. As with any immune system responders, we suspect that CTL sometimes mistarget or misidentify receptors and thus kill healthy cells or misidentify self versus antigen. But again for the sake of simplicity, we do not attempt to model that here.
Parameter Specifications
The model (2.1) contains numerous parameters that must be assigned values before simulations can be carried out. In specifying model parameters, to the greatest extent possible we employ values similar to those reported or justified in the literature. The parameters indicated in Table  1 are principally extracted from the Callaway-Perelson [14] and Bonhoeffer, et al., [9] papers.
Callaway and Perelson point out that several model parameters are not available from human or animal data. They choose the parameters λ 1 , k 1 , λ 2 , and k 2 such that several conditions on target cell and viral load equilibria are satisfied for their model. We note that these conditions are not precisely satisfied by our model which has no chronic cell compartment and an added immune response. However, the conditions are closely approximated by the model's behavior and we believe the parameters could be adjusted to obtain the same qualitative behavior. Further explanation of these criteria appears below.
In general, immune response parameters are not well known and are thus frequently chosen to demonstrate model behavior in simulations. The parameters m 1 and m 2 represent cytopathicity of the immune effectors. Their common value was taken from [14] where the authors note that the value was suggested originally by Nowak and Bangham [47] . We scale the parameter K b by a factor of 1000 since the Bonhoeffer paper appears to use units of microliters, whereas we consider infected cells per milliliter. The parameter K d is adjusted by a factor of 100 in order to demonstrate the possibility of multiple stable equilibria for the model. 
Model Steady States and Simulation
Given the specified parameters, in the absence of therapy, the model exhibits several steady states as shown in Table 2 . Equilibrium EQ 1 represents the uninfected patient, with healthy T-cell counts and no virus or infected cells present. When the system is in this state, introduction of a small amount of virus causes the system to converge to EQ 3 , where healthy target cells are substantially depleted and a dangerously high viral load is present. The system also exhibits a second stable equilibrium EQ 4 , where a strong immune response has developed, successfully controlling the virus and consequently restoring target cell (T 1 ) help. We turn to the criteria on the steady states suggested by Callaway and Perelson. When = 1 and f = 0, they desire a viral load of 100. In this scenario, our model exhibits a viral load of V = 143 c/ml, which is on that order. The equilibrium is:
When = 1 and f = 0.5, they desire eradication of the virus. Our model does not precisely attain that, though the viral steady state (V = 43 c/ml) is below the limit of detection for most assays currently in use. The complete equilibrium is given by:
Further, by increasing the treatment efficacy factor to f = 0.6, the virus is eradicated because the uninfected steady state becomes stable. Figure 1 depicts the sensitivity of the viral load equilibrium to drug efficacy . The introduction of the immune response terms causes a discontinuity in this curve as stability is exchanged between viral dominant and immune-dominant equilibria. This is in contrast to the sensitivity curve of the original Callaway-Perelson model which is continuous across the range of drug efficacies. However, this may be reasonable -a certain amount of drug may be necessary to augment the immune system to counteract effects of the virus. The low (nonzero) steady state viral load is maintained across the entire range of reasonable drug efficacies. The model also exhibits approximately a 1-2 log drop in viral load across the range of drug efficacies, which is typical for monotherapy with RT inhibitors. A simulation of early infection is shown in Figure 2 . Simulation is started near steady state EQ 1 , with the addition of one (1) viral copy per ml (V = 1 c/ml). Upon infection, the virus replicates to a peak before converging in damped oscillations to equilibrium. There is a delayed initial immune response to the presence of the infected cells, but a sustained and vigorous immune response does not develop. The higher infection rate in the T 2 population is evident in its more dramatic decline than the T 1 cell population. 
Sample Inverse Problem Calculation and Standard Error Estimates
As discussed above, if one wishes to use a mathematical model to make predictions about a particular individual or population, estimation of model parameters from data is crucial. In this section, we outline an inverse problem methodology for estimating parameters and associated uncertainty from single patient data. We use simulated data generated in a manner that respects conditions encountered in clinical studies. It is generally a standard (and wise) practice to test one's inverse algorithms on simulated data before attempting to use them with experimental or clinical data.
Simulated Data Generation
In generating simulated data for a single patient, we assume that measurement error is a dominant source of variation and that measurements of different system states (e.g., T 1 and V ) are independent at any given time. This is valid for certain, but not all, assays, and a reasonable assumption given that the assays here are not performed sequentially but independently on distinct portions of the same specimen or on entirely different specimens. Measurements over time in clinical studies are generally taken on a given patient at intervals sufficiently separated in time that correlation over time may be reasonably taken as negligible. We thus assume further that measurements over time are independent and take typical measurement intervals of 3 to 10 days. Assume that the mean response for measurements on a single patient is given by the solution to the ODE model with some true parameter vector q 0 . Specifically, letx = ( . However, this model allows the possibility of generation of unrealistic negative measurements, making the lognormal a more natural choice for our systems and data.
We employ this method to generate simulated data with coefficient of variation σ i = 0.20 for each state, which is in the range observed in practice for viral load and CD4 count assays (see, e.g., [69, 62] ). As above, we consider the early infection scenario, with parameters previously specified. We consider two scenarios -one where all six states are observed and one where there are only three observed quantities: (T 1 + T * 1 ), V , and E, as is typical in our clinical data sets.
Semi-relative Sensitivity Analysis
As a first step in testing the feasibility of inverse problem calculations, we attempt to estimate those parameters to which the model solution is most sensitive. These, in turn, are determined through a semi-relative sensitivity calculation.
To describe this methodology, suppose we wish to determine the relative sensitivity of the observed model quantities x (and consequently the model solutionx) to particular parameters q k , k = 1, . . . , r. The semi-relative sensitivity of the model solution to parameter q k is given by
(see [4] ) and is computed by formally differentiating the ODE model
with respect to q k and interchanging the order of the time and parameter derivatives as outlined in [4, 19, 22] . In the case of r parameters and n state variables, we thus obtain an (n × r)-dimensional system of differential equations for the sensitivitiesx q (t; q) = ∂x ∂q (t; q), where q is the vector of parameters considered:
with initial condition ∂x(0) ∂q
The latter is simply the zero matrix whenever the initial condition is not a function of any of the parameters estimated. Here ∂f ∂x is the Jacobian of the ODE system, and ∂f ∂q the derivative of the right side with respect to the parameters considered.
We solve {(3.3),(3.4)} forx q (t; q) by coupling it with the original differential equation system to obtain an (nr + n)-dimensional system which we solve numerically with a Matlab ODE solver. For another application of this methodology see [1] . Since our observation process on the model states is linear in these states, we can apply the observer C to these sensitivities to obtain the sensitivities x q (t; q) for the relevant observed model quantities.
This process yields sensitivity information as a function of time over the interval of interest. We wish to have some overall measure of the sensitivity of the solution to the parameters, so for each state / parameter combination, we take a norm in time and then rank the resulting scalars to determine the most sensitive parameters. We find that these comparisons are similar using the two or sup norm -and report using the two norm here. Also, most of the interesting system dynamics occur in the first 50 days, so using a longer time span for these computations does not affect the results.
Fixing the parameters in (2.1) that have already been estimated from human or monkey data as known, we find that of the remaining parameters, the model solutions (especially states T 1 and V ) are most sensitive to the parameters k 1 , λ 1 , k 2 , and λ 2 (see Table 3 ). Several other parameters follow closely with less relative sensitivity, including b E , d E , and δ E . Parameters near the end of the chart are likely more difficult to estimate from data.
Since the parameter = 0 for these simulations, we find that as expected the model solution is completely insensitive to the treatment parameters and f . When considering a scenario with
3.98107e-02 Table 3 : Ranked semi-relative sensitivity of various model states to parameters not previously estimated from human or monkey data.
treatment > 0, the model solutions are highly sensitive to these parameters (results omitted). We also note that when only making partial state observations, the observables are most sensitive to these parameters in the same order as reported here. There are alternate methods for computing the sensitivity matrix -see [6] for another efficient approach for some systems. For example, in [6] , the authors determine the sensitivities x q by taking forward difference quotient approximations near q. This replaces the sensitivity equation solution step with r extra solves of the ODE system. We note that for the initial conditions and parameters considered here it seems to make a considerable difference whether one uses one-sided (forward) or centered differences to approximate the derivatives. The latter provide much more accurate derivative information, at twice the computational cost.
Parameter Estimation Algorithm
We estimate the parameters from ρ observed quantities simultaneously based on data from N time points. The state variable observations are potentially different from each other by orders of magnitude, so, intuitively, it is critical that the estimation scheme take this into account. One way to do this is by appropriately weighting the states in a least squares cost criterion. Formal statistical large sample theory implies that the optimal (in the sense of yielding the estimator for the true value q 0 making most efficient use of the data when N is large) least squares criterion uses weights equal to the inverse of the true model for variance [14] . Such weighting may be implemented via an iterative generalized least squares (GLS) algorithm based on the mean model
. . . . . .
for the data at each time point t j . To calculate initial weights for the GLS algorithm, we perform a preliminary weighted least squares estimation. We minimize a least squares objective functional over admissible parameters q to obtain the initial estimate q 
where q (0) is the initial iterate for the estimation process. The estimation proceeds with the following iterative algorithm: Set k = 1.
Estimate coefficients of variation σ
2 i for each state:
where we recall that r is the dimension of the free parameter vector q;
Form estimated weights
3. Minimize the weighted least squares cost function to obtain the next estimate
4. Set k = k + 1 and repeat steps 1.-3. until convergence. One can use either a fixed number of GLS iterations, or iterate until the relative change in the parameter vector q is small (say 10 −6 ). The results that follow use the former criterion with a preliminary estimate followed by five GLS iterations.
We will denote the resulting optimal parameter vector estimate by q * .
Standard Error Calculation
When estimating parameters using a procedure such as the one given above, it is vital to understand the uncertainty of the estimation process, that is, any estimate of mean model parameters from data should be accompanied by an estimate of uncertainty. Here we assess the variance in the estimated model parameters q * by computing standard errors. The method here is a more general version of that described in Davidian and Giltinan [16] and uses sensitivity equations for derivative information, as described above. An example of this methodology in the single state case can be seen in [1] .
We stack the model responses X = x X q is a ρN × r matrix. ) To obtain standard errors, this is computed at the optimal estimate for the parameters: X q (q * ). Recall that we assume that the measurement process errors are independently distributed. With our assumed model for the distribution of the data, we expect the GLS estimateq = q * to be approximately normally distributed (at least asymptotically). Specifically, for large samples,
3). (Thus
where q 0 is the true vector of parameters and the true covariance matrix is
Here G is the weighting matrix Having no better approximation to the true values q 0 available, we follow standard statistical practice and substitute the computed estimate q * for q 0 in the above matrices in (3.12) to obtain standard errors for our estimates. In particular, taking Σ from (3.12) above (taken with the described substitutions), we then take √ Σ kk to obtain the standard error for parameter component k.
Inverse Problem Results
To illustrate the type of information that can be obtained using the methodology discussed above, we present results for several inverse problems, considering first the case with full state observations (T 1 , T 2 , T * 1 , T * 2 , V, E) as well as a case with partial state observations (T 1 +T *
, V, E).
The latter case is representative of the type of clinical data discussed in Section 4. The data used simulated measurements every five days from 0 to 200 days, inclusive. We estimate three subsets of the model parameters: k 1 only, k 2 only, and the pair k 1 , k 2 jointly. Recall that the simulated data are generated with true parameters k 1 = 8.0 × 10 −7 and k 2 = 1.0 × 10 −4 . These infectivity parameters are important to estimate since they describe the viral infection rate for the two cell populations and the overall system dynamics are highly sensitive to them. To estimate k 1 and k 2 jointly, we consider five initial iterates taken as ordered pairs from the iterates used for single parameter estimation above. When using full state observations, the algorithm returns the same parameter pair for each initial iterate pair:
−7 , 9.3961 × 10 −5 ) with corresponding standard errors (5.0385 × 10 −9 , 1.5997 × 10 −6 ) and cost function values of 117 (weighted) and 3.7172e+11 (unweighted). The fit to data can be viewed in Figure 3 , where the solid lines are the simulations corresponding to the optimized parameters q * . For partial state observations we obtain similar results, although the initial iterate (10 −8 , 10 −6 ) does not lead to convergence within the allotted five GLS iterations. (This is the only such exception among the results presented here.) Overall though, for the joint estimation case, the algorithm is relatively robust to the choice of initial iterates (see Table 5 ). Figure 4 depicts a typical fit to the partial state data. Even with only observations of T 1 + T * 1 , V, and E, the estimation process yields acceptable estimates of k 2 , although the large standard errors do not lend a lot of confidence to their accuracy.
In a forthcoming paper, we will explore the ability to fit this model with greater numbers of free parameters and discuss the merits of different weighting schemes in the estimation process. As an alternative to the methodology presented here, one could use sampling-based methods, such as Monte Carlo Markov Chain algorithms, to obtain parameter information from data. These methods yield an estimate for the distribution of a parameter (and hence estimates of the mean and variance similar to those we have reported here). Our group is currently comparing the efficiency of such methods to those discussed in this paper.
Modeling HIV Dynamics: A POD Approach
There are many families of patterns occurring in both nature and in the sciences for which it is possible to obtain a useful systematic characterization. Often, the motivation is that the family is of low dimension, that is, in some sense, any given member of the family might be represented by a small number of parameters. Examples of these pattern families occur in turbulent flows [40, 3, 60, 7] , image processing [28, 63] , data compression [2] , human speech [64] , and human faces [34] . In these applications the technique used to represent such characteristics is known as the proper orthogonal decomposition (POD). In other disciplines it also called the Karhunen-Loève decomposition [38] , principal component analysis [30] , and the Hotelling transform [24] .
Typically, the POD procedure is implemented in engineering or science applications where the physical or biological system may be described by a mathematical model, i.e., a nonlinear distributed parameter system with boundary and initial conditions. The pedagogy to obtain the governing equations begins with some simplifying assumptions about the physical or biological system and then applies first principles to derive quantitative models. The POD procedure, applied together with the Galerkin, finite element, finite volume, or spectral method, results in a reduced order model which represents the underlying low dimensional system.
On the other hand, many problems in engineering and medicine, including HIV population level dynamics, are sufficiently complex that a mathematical description is either nearly impossible, or when a model is obtained, it can not be implemented without undue complications. For example, the degree of freedom of distributed parameter systems is essentially infinite, and in the case of HIV population level models, the parameters are often formulated as random variables in order to accurately account for various sources of variability contained in aggregate clinical data. It is possible to apply the POD method to an ensemble of data (with or without an underlying model) to extract a basis that characterizes the salient features of the ensemble. In this section, we assume that the mathematical model for HIV dynamics is not yet known, but data to be used to guide and validate model development is available. Our primary goal is to show that characteristic features, extracted from collected data using the POD procedure, can be used to organize HIV data (RNA viral load values) more efficiently and accurately.
HIV STI Clinical Data
The data that we employ for our demonstration were collected by one of the authors (Rosenberg) from patients studied at Massachusetts General Hospital. The ensemble provides RNA viral load, CD4, and CD8 data for 102 patients. Approximately 40 patients have at least one treatment interruption, and some have as many as four treatment interruptions. The interruptions are either approved according to protocol, are due to illness or drug toxicity, or are patient initiated.
The data set contains a high degree of variability. For an individual patient viral load values may range from a censored value of fifty (c/ml) to several million (c/ml); the duration of the interruptions range from one week to several years. We have inter-patient variability (long-term non-progressors versus rapid progressors) as well as intra-patient variability (on treatment, off treatment, poor adherence, short drug holidays, or structured treatment interruptions).
The Proper Orthogonal Decomposition
In the following we provide a basic description of the POD method; a more detailed description is given in [42] . Let U i = U i (t), i = 1, 2, . . . , N , denote the set of N observations (also called snapshots) for t ∈ Ω, Ω bounded. For example, U i could represent the RNA values observed for patient i at times t ∈ Ω. We wish to find an optimal compressed description of the sequence of data. One description of the process is a series expansion in terms of a set of basis functions. Intuitively, the basis functions should in some sense be representative of the members of the ensemble. Such a coordinate system is provided by the Karhunen-Loève expansion, where the basis functions Φ are, in fact, linear combinations of the snapshots and are given by
Here, the coefficients a i are to be determined so that Φ given by (4.1) will most resemble the ensemble
. Indeed, it follows that (see, e.g., [42] ) the coefficients a i are the entries of the i th eigenvector corresponding to the i th largest eigenvalue of the N × N covariance matrix
where
It is noted that the covariance matrix is a symmetric and nonnegative matrix and, hence, the eigenvalues, λ i are real and nonnegative. We arrange the eigenvalues in decreasing order as λ 1 ≥ λ 2 ≥ · · · λ N ≥ 0. Thus Φ 1 is the basis function corresponding to the largest eigenvalue. Any snapshot in the ensemble can be represented as a linear combination of the basis functions as follows
Employing only the first M POD basis elements, we obtain the approximation U
M i
for U i such that
It is well known that (see, e.g., [42] ) expansion (4.4) is in some sense optimal. In particular, among all linear combinations, the POD is the most efficient, in the sense that, for a given number of modes M, the POD decomposition will capture the most possible kinetic energy. One way to quantify the error of the approximation is by computing the relative error
ER(U
M i ) = U i − U M i L 2 (Ω) U i L 2 (Ω) . (4.5)
RNA Modeling Results and Discussions
In this section, we demonstrate the effectiveness of using the POD expansion to model RNA values on an ensemble clinical data set collected at Massachusetts General Hospital. One could use the entire data set for the ensemble, using each patient as a snapshot. Indeed, initially we followed this approach with very limited success. This was due to the significant inter-patient and intra-patient variability observed in the data set. This contributed to the difficulty in representing the data by a reduced POD basis. Here, we first focus on a subset of the data ensemble -HIV patients that undergo treatment interruptions. We focus only on data points that correspond to ON treatment entries. Modeling of the OFF treatment entries will be addressed later. Before applying the POD method to the restricted set of ON segments (snapshots), we first perform some preliminary data manipulations to obtain a more realistic "guess" of the OFF/ON treatment cycle. For example, in looking at the RNA data we often encountered segments similar to the following: date on/off RNA value comment 1/22/02 off 750,000 no medication 1/24/02 on start medication 1/30/02 on 1000
In this example, the 1/24/02 entry has no RNA value, and is ignored (deleted). As a result, the ON segment begins on 1/30/02 with a relatively low RNA value of 1000. For this example we would modify the data by copying the previous OFF treatment value as follows: date on/off RNA value comment 1/22/02 off 750,000 no medication 1/24/02 on 750,000 start medication 1/30/02 on 1000
We feel this is a more realistic guess of the OFF/ON cycle. We did this for patient segments where a relatively recent OFF value was available, normally within one week of starting medications. If no recent OFF value was available, we left the data as is.
With these data modifications, we obtain 78 snapshots of RNA data for patients starting and continuing on treatment. The length of these segments vary from 13 days to 1421 days. The general ON profile starts with high viral load, it rapidly decreases due to medication, and then typically stays small (i.e., censored data).
To apply the POD method to the set of HIV ON snapshots, the snapshots should be defined on a similar time interval, i.e., Ω = [0, T ]. We start all snapshots at day zero, and then interpolate each snapshot onto a common (merged) set of time points. The ON snapshots are of variable length, i.e., U i (t) is defined on [0, T i ] and not on [0, T ], except for T = min{T i } small. We deal with the variable data length in one of two ways: we truncate a subset of patient data defined on [0, T ON ] for a set of fixed length snapshots, or we compute the 'covariance' matrix C u with variable length time series. For the later, C u is computed as
To apply the POD method to fixed length vectors, we extract a subset of segments with length greater than T ON and then truncate. For example, if T ON = 482 days, the subset includes 18 snapshots. A reduced order basis may be used to approximate the subset of truncated ON snapshots. The full POD basis may also be used to approximate the additional 60 ON segments, outside the subset of snapshots used to generate the POD basis, using approximation (4.4) computed on [0, T i ] for T i < T ON . In general, the relative error for the shorter snapshots is not great.
The POD method applied to the 78 variable length ON segments produces 78 POD basis elements defined on T max = max T i . We can reconstruct all 78 ON segments using approximation (4.4) with M = 18 POD basis elements to obtain a 5% average relative error. Nine snapshots have a relative error greater than 10%, i.e., ER(U M i ) > 0.1. In Figure 5 we compare the relative errors of the fixed length POD approximations to the variable length POD approximations. In either case, the approximation is computed with M = 18 basis elements. The POD method based on the variable length snapshots obtains better overall approximations. The ability to successfully approximate most ON segments is likely due to the apparently homogeneous nature of patient profiles while on treatment. With good adherence to drugs, the RNA profile of most patients on treatment is relatively flat, i.e., the RNA values are (<)50 or (<)400, depending on the assay.
Given the variability of the data and the sometimes incomplete data records, we relax the notion of approximating all ON snapshots well. If we delete the nine snapshots with the worst POD approximation relative error from the ON treatment ensemble, 69 ON snapshots remain. Applying the POD method to these remaining variable length ON segments, we again use M = 18 basis elements to reconstruct the snapshots. All remaining snapshots have a less than 10% approximation relative error, with max(ER(U M i )) = 0.06 and mean(ER(U M i )) = 0.02 (see Figure  6 ). Fewer basis vectors may be used, but the relative error increases rapidly for one segment in particular. See also Figures 7 and 8 for the POD approximation of the 3 ON segments with the best and worst approximation relative error, respectively.
Next we turn to the original ensemble including all 102 patients, patients with treatment interruptions and with no treatment interruptions. We repeat the same process: manipulating the data to more accurately represent the ON/OFF treatment cycle using a slightly more rigorous protocol, and then extracting the ON segments. We obtain 138 ON segments with lengths varying from 4 days to 1833 days. We apply the POD method to the variable length ON snapshots, use M = 33 POD basis elements to approximate the snapshots, and identify and remove the 9 snapshots with more than 10% approximation relative error. If we rerun the POD method, again using M = 33 POD basis elements for approximation, we obtain good overall relative error (i.e., max(ER(U M i )) = 0.084 and mean(ER(U M i )) = 0.014) (see Figure 9) . Similarly, we have attempted to approximate the OFF treatment snapshots from patients with treatment interruptions. To date, the results are not as promising; the OFF segments achieve a 20% average approximation error. This is most likely due to the inhomogeneity of the OFF snapshots. Some patients maintain a low viral load after discontinuing treatment, some experience viral rebound and decline during treatment interruptions, while others exhibit a slow, steady increase in viral load. All of these scenarios are included in the OFF treatment ensemble. Future effort will include the application of the POD method to subgroups within the OFF Procedures such as those described here should prove quite useful in selecting subsets of clinical data for use with the model fitting and validation methods presented in Section 3.
An Optimal Control Problem
In this section, we consider optimal control methods to derive optimal drug treatments as functions of time. We attempt to control HIV populations in finite time intervals using a control function (t) which represents the drug efficacy satisfying 0 ≤ a ≤ (t) ≤ b < 1. Here (t) = b represents maximal efficacy, where we tacitly assume that we control efficacy by simply controlling the dose level. Together with the model described by equation (2.1) for HIV infection we consider a cost functional given by
where Q and R are weight constants of virus and control, respectively. The second term represents systemic costs of the drug treatment. Our goal is to minimize both the HIV virus population and the systemic cost to body. We seek an optimal control * such that
} is the control set. Given the criterion (5.1) and the regularity of the system in our model equations (2.1), it is rather straightforward to establish existence of optimal controls by relying on standard results in control theory (e.g., see [21] ). We turn therefore to methods for computation of optimal controls.
Optimality System
Since an optimal control exists for minimizing the cost functional (5.1) subject to (2.1), we present necessary conditions for optimality (see, e.g., [33] for details on these procedures). These can be used to compute candidates for optimal controls (which may or may not be uniquely determined).
Given an optimal control * and solutions of the corresponding state system (2.1), we can define adjoint variables ξ i , i = 1, · · · , 6, as follows:
Using these we find that an optimal control * is given by * = max a, min b,
To see this, define the Lagrangian (which is the Hamiltonian augmented with penalty terms for the constraints) to be:
where w 1 (t) ≥ 0, w 2 (t) ≥ 0 are the penalty multipliers satisfying w 1 (t)( (t) − a) = 0 and w 2 (t)(b − (t)) = 0 at optimal controls * .
We differentiate the Lagrangian with respect to states, T 1 , T 2 , T * 1 , T * 2 , V, and E, respectively, to obtain the following equations for the adjoint variableṡ
By differentiating the Lagrangian L with respect to , we also have
Solving for the optimal control we find
To determine an explicit expression for an optimal control without w 1 and w 2 , we consider the following three cases:
(i) On the set {t|a < * (t) < b}, we have w 1 (t) = w 2 (t) = 0. Hence the optimal control is * = −(
(ii) On the set {t| * (t) = b}, we have w 1 (t) = 0. Hence
which implies that
(iii) On the set {t| * (t) = a}, we have w 2 (t) = 0. Hence
Since w 1 (t) ≥ 0, it follows that
Combining these three cases, we obtain the optimal control given by (5.3).
The optimality system thus consists of the state system (2.1) coupled with the adjoint system (5.2) with the initial conditions and terminal conditions together with the relationship (5.3). Any optimal controls must satisfy this system.
Continuous Optimal Treatment
The optimality system is a two-point boundary value problem since it includes initial conditions specified for the state equations and terminal conditions specified for the adjoint or costate system. We use a gradient method for solving the optimality system. The state system (2.1) with initial conditions is solved forward in time using an initial guess for the control and then the adjoint system (5.2) with terminal conditions is solved backward in time. The controls are updated in each iteration using the formula (5.3) for optimal controls. The iterations continue until convergence is achieved. For further discussion of this iterative method we refer the interested reader to [26] . The parameters used in solving the optimality system are summarized in Table  2 .1. Treatment was simulated for 100 days.
We simulate early infection by introducing one virus particle per ml of blood plasma, i.e., T 1 (0) = 10 6 , T 2 (0) = 3198, T * 1 (0) = 10 −4 , T * 2 (0) = 10 −4 , V (0) = 1 and E(0) = 10. In addition, we use a = 0 and b = 0.8. We ran simulations with three different values of weight factor R. The corresponding optimal control functions are presented in Figure 10 . As we increase R, thereby increasing the cost of therapy, the optimal control function is decreasing. In the other figures presented in this section, we present only the case Q = 0.1 and R = 10000 for brevity. Since the magnitude of virus population is much larger than the magnitude of the cost of the drug treatment in the objective function (5.1), this difference in magnitude is balanced by this choice of Q and R.
We solve the HIV model (2.1) with no treatment ( ≡ 0) and with fully efficacious treatment ( ≡ 0.8). The numerical results for these two cases as well as the optimal case are presented in Figure 11 for comparison. The corresponding values of the objective functional for all cases are given in Table 6 . As depicted in Figure 11 the optimal solutions are very close to the solutions corresponding to the fully efficacious treatment. However, the optimal cost is smaller than the cost functional corresponding to the fully efficacious treatment case. 
An Optimal STI Control Problem
In Section 5 we formulated and synthesized continuous optimal control solutions for a modelbased infection treatment. However, this type of (continuous) treatment, especially, for long periods is difficult to maintain due to possible long-term toxicity of the drugs as well as possible development of resistance to medications. In this section we consider the optimal control of viremia through a number of drug structured treatment interruptions (STI).
To this end, we assume our control is a 1 × 100 vector which consists of only 0 or b in each vector element. If an element of a control vector is 0, it signifies drug treatment being off on that day and if an element of a control vector is b, it represents full drug treatment being on. Since we consider a drug treatment strategy over 100 days, the size of is 1 × 100. The set of all such control vectors is denoted by Λ. The goal is to seek the optimal control vector * satisfying
subject to the state system (2.1) and where J( ) is defined by (5.1).
Since the number of elements of the set Λ is finite, existence of an optimal control solution is guaranteed. To find the discrete STI optimal solution, we could use a direct search approach and begin by selecting any element in the set Λ and then solving the state system using this element as a control. We next would select another element in the set Λ and solve again the state system using the element as a control. Then we compare the values of the objective functional, J, and select the element corresponding to the smaller cost functional value. If we iterate this strategy over all elements in the set Λ, we obtain the optimal control solution * . However, this strategy to obtain the discrete optimal solution can lead to a large number of cost functional evaluations (and hence a large number of solutions to equation (2.1)). In our case, where the control vector is a 1 × 100 vector, the number of cost functional evaluations would be 2 100 , rendering this approach computationally impractical.
There are several ideas that we considered to reduce the number of iterations. The simplest approach is to consider, for illustration, a 5 day segment (instead of a one day segment as above). This is reasonable from a practical point of view because it is not reasonable to have drug on one day and off the next day. For a 5 day segment, the size of the control vector is reduced to 1 × 20 from 1 × 100. Hence, the number of iterations to find the discrete optimal STI solution is now 2 20 instead of 2 100 . Using the above iterative reduction technique, we obtained the optimal 5 day segment STI which is depicted in Figure 12 . The associated optimal state solutions are shown in Figure 13 . As depicted in Figure 12 , the optimal 5 day segment STI strategy is that drug is off for the first 25 days, drug is on for the next 5 days, drug is off for the next 10 days, and so on. In addition, Figure 13 reveals that solutions of the state system with the optimal STI control are similar to solutions with no treatment up to the 25th day. After that, the population of uninfected T 1 cells with STI approaches the population of uninfected T 1 cells with full treatment and the virus population is also maintained at a low level. Moreover, the immune effectors (E) with STI have larger values than in the other cases. That is, this optimal STI control boosts the immune effectors (E) while reducing virus load and increasing uninfected T 1 and T 2 cells over the treatment period. 
STI Control Problem with Long Time Horizon
The above reduced iterative approach is still not computationally efficient for long time treatment regimens. For example, if one considers a treatment interruption strategy over 400 days duration of therapy, the resulting required number of cost functional evaluations is 2 80 for a 5 day segment, which is still considerably large. One approach to mitigate this shortcoming is to consider subperiods of the given period such as [0, 50] , , , , , , , , , ) where is 0 or b.
That is, we fix the optimal STI * 1 as the first 10 elements of the control, and iterate 2 to find the last 10 elements of 2 . In this case, the number of iterations is again just 2 10 . We repeat this process to find an optimal STI control, * is only suboptimal. However, our initial efforts suggest that it is a good approximation to the optimal STI control. In particular, the suboptimal STI control over [0, 100] that is obtained using the above subperiod method is almost identical (visually) to the optimal control using the reduced iterative method from above. Using the subperiod method (which might be viewed as a type of dynamic programming idea), the suboptimal STI control and its associated suboptimal solutions are depicted in Figure 14 and Figure 15 , respectively. It is noted that the dynamics of uninfected T 1 cells with suboptimal STI control and full treatment are very close and the virus is also maintained at a low level. Moreover, the immune effectors with suboptimal STI control are maintained at a high level while the immune effectors with full treatment are at a lower level.
Finally, we consider a treatment interruption protocol where we apply suboptimal STI for the first treatment period [0, 300] then follow with full treatment over the final period [300, 400]. As depicted in Figure 16 we see a substantial increase in the population of uninfected T 2 cells with suboptimal STI control followed by full treatment over [300, 400] . In addition, the immune effectors with the suboptimal STI and full treatment are also much higher on the 400th day. This increase in immune effectors allows the virus to maintain a small population. However, if we have full treatment for too long, (for example, if we consider a suboptimal STI over [0, 200] and follow with full treatment over [200, 400] ), the immune effectors are increasing until around the 300 th day and are decreasing after the 300 th day. 
Concluding Remarks
In this paper we have attempted to discuss a number of important issues relative to the investigation of HIV infection and treatment. The mathematical and statistical ideas we include are not meant to be exhaustive; rather they reflect some of those that our own experiences suggest are relevant. Moreover, the model we employed to illustrate these tools and techniques is not proposed as a penultimate model; it is simply one that we feel possesses certain features that we and other investigators believe are relevant in trying to understand quantitative and qualitative aspects of a very complex immunological process. We do think that the techniques and methodologies presented here will be useful as more sophisticated and "biologically correct" models are developed in the near future.
